Why Is Phreesia (PHR) Stock Down -26% Today?
Key Takeaways
- PHR shares are plunging approximately 26.64% in premarket trading on March 31, 2026, falling from a prior close of $11.41 to $8.37.
- The primary catalyst is a significant downward revision to fiscal 2027 revenue guidance, cutting the midpoint outlook by roughly $37 million.
- Phreesia cited reduced spending commitments from pharmaceutical manufacturers due to brand-specific dynamics and regulatory policy impacts as the key driver behind the guidance cut.
- Q4 FY2026 adjusted EPS of $0.02 missed analyst estimates of $0.06, adding to investor disappointment despite a slight revenue beat.
- Multiple Wall Street analysts slashed price targets in response, with Needham reducing its target by 60% — from $35 to $14 — while maintaining a "Buy" rating.
- Traders are watching whether the stock stabilizes near multi-year lows and how management addresses pharma revenue exposure going forward.
Opening Summary
Phreesia, Inc. (PHR) is a healthcare technology company that provides software solutions to streamline patient intake, financial operations, and engagement for healthcare organizations across the United States. In premarket trading on March 31, 2026, shares are down approximately 26.64%, collapsing from a prior closing price of $11.41 to around $8.37 — a decline of roughly $3.04 per share. The selloff was triggered by the company's fiscal Q4 2026 earnings report, released after the close on March 30, 2026, which featured a meaningful earnings miss and a sharply reduced revenue outlook for the upcoming fiscal year.
Guidance Cut Spooks Investors
The headline driver of PHR's premarket plunge is a steep revision to its fiscal 2027 revenue guidance. Phreesia lowered its FY2027 revenue forecast to a range of $510 million to $520 million, down from its prior guidance of $545 million to $559 million — a reduction of approximately $37 million at the midpoint. The company attributed the cut to lower spending commitments from certain pharmaceutical manufacturers, particularly in its network solutions segment, where clients have reduced committed spend levels for the second half of fiscal 2027 due to brand-specific dynamics and regulatory policy impacts.
The revised guidance also reflects a downgrade in total revenue per healthcare services client (AHSC) growth expectations — from low-double-digit percentage growth to only low-single-digit percentage growth in FY2027. This is a meaningful deceleration and signals increasing uncertainty in Phreesia's highest-growth revenue stream.
Earnings Miss Adds to the Pressure
Beyond the guidance reduction, PHR's Q4 adjusted earnings per share came in at just $0.02, missing analyst consensus estimates of $0.06 by $0.04. This EPS shortfall, while modest in absolute terms, amplified investor concern about the company's ability to execute as revenue growth moderates. On the revenue side, Q4 results were marginally better — $127.1 million versus the consensus estimate of approximately $126.86 million, representing a 16% year-over-year increase — but that slim beat was insufficient to offset the damage from the guidance cut.
For the full fiscal year 2026, Phreesia did achieve several notable milestones: total revenue of $480.6 million (up 14% year-over-year), first-ever positive GAAP net income of $2.3 million, Adjusted EBITDA of $101.5 million (up from $36.8 million in FY2025), and free cash flow of $54.4 million. However, these achievements were overshadowed by forward-looking concerns.
Analyst Downgrades and Target Cuts
Wall Street's reaction was swift and severe. Needham analyst Ryan MacDonald maintained a "Buy" rating on PHR but slashed the price target by 60% — from $35.00 to $14.00 — reflecting the dramatically changed revenue trajectory. This follows a pattern of rolling analyst target reductions in recent months: Wells Fargo cut its target from $30 to $25 on March 26, Mizuho lowered its target from $22 to $19 on March 24, and JP Morgan reduced its target from $29 to $24 in February. The consensus remains broadly constructive on a rating basis, but the magnitude of price target reductions signals a significant reset in growth expectations.
Market Context and Trading Activity
PHR was already under significant pressure entering this earnings report. The stock had recently set a 52-week low of $10.75 in mid-March 2026 and had declined more than 32% over the prior three months. The premarket volume of approximately 42,000 shares suggests elevated activity relative to normal premarket norms, consistent with a sharp earnings-driven move. The broader healthcare technology sector has faced headwinds from both macro uncertainty and regulatory pressures on pharmaceutical marketing budgets — the same dynamics now explicitly cited by Phreesia as a drag on its business.
From a technical standpoint, the premarket print of approximately $8.37 breaches the prior 52-week low, placing PHR in uncharted territory on its recent trading range. The stock's 50-day simple moving average stood at $14.14 and the 200-day at $19.61 before this session, meaning the stock is now trading at a severe discount to both key trend measures.
Trending AI Robots
For traders navigating volatile, earnings-driven moves like today's action in PHR, Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing automated trading strategies. Tickeron operates hundreds of AI-powered bots covering thousands of tickers, but only those demonstrating the strongest performance under current market conditions are featured in the Trending AI Robots section. Each bot varies by trading strategy, time horizon, performance metrics, and the specific symbols it trades — giving investors a range of options tailored to different risk profiles and market environments. Whether navigating high-volatility events or seeking systematic exposure to sector trends, exploring the Trending AI Robots page is a practical starting point for traders looking to put data-driven tools to work.
What Comes Next for PHR
Looking ahead, investors will closely monitor whether Phreesia can stabilize pharmaceutical-related revenue commitments as it enters fiscal 2027. Management noted visibility into pharma spending remains limited, suggesting near-term uncertainty in the network solutions segment is unlikely to resolve quickly. Notably, Phreesia maintained its FY2027 Adjusted EBITDA guidance of $125 million to $135 million despite the revenue reduction, indicating the company believes it can absorb the shortfall through AI-driven operational efficiencies and cost controls — a thesis investors will want to see demonstrated in upcoming quarterly results.
The company's next earnings report — its fiscal Q1 2027 results — is expected in late May or early June 2026, which will be the first meaningful test of whether the pharma spending headwind is stabilizing or deepening. Analysts will also be watching subscription revenue trends and AHSC growth closely, given the downgraded per-client revenue outlook. With the stock now approaching or breaching multi-year lows, sentiment has materially deteriorated, and any recovery will likely require tangible evidence that FY2027 guidance is achievable.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PHR's Indicator enters downward trend
The Aroon Indicator for PHR entered a downward trend on April 10, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 241 similar instances where the Aroon Indicator formed such a pattern. In of the 241 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on March 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PHR as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for PHR turned negative on March 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PHR's RSI Oscillator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PHR advanced for three days, in of 307 cases, the price rose further within the following month. The odds of a continued upward trend are .
PHR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.550) is normal, around the industry mean (16.159). P/E Ratio (215.000) is within average values for comparable stocks, (88.661). PHR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.826). PHR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.032). P/S Ratio (1.100) is also within normal values, averaging (70.098).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PHR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of patient check-in solutions for medical practices
Industry ServicestotheHealthIndustry
Advertisement